Orodispersible and Transmucosal Alternative Medications

For Symptom Control in Adults

Corresponding Author: Anna Sutherland; annasutherland@doctors.org.uk; Sir Michael Sobell House Hospice, Churchill Hospital, Old Road, Oxford OX3 7LE;

Co - Authors: *Melinda Presland*, Sir Michael Sobell House Hospice, Churchill Hospital, Old Road, Oxford OX3 7LE; *E Harrop*, Consultant in Paediatric Palliative Care & Medical Director, Helen & Douglas House, 37 Leopold Street, Oxford, OX4 1QT & Honorary Consultant Oxford University Hospitals NHS Trust Churchill Hospital, Old Road, Oxford OX3 7LE; *Matthew Carey*, Sir Michael Sobell House Hospice, Churchill Hospital, Old Road, Oxford OX3 7LE, ORCID ID 0000-0002-6092-2512; Mary Miller, Sir Michael Sobell House Hospice, Churchill Hospital, Old Road, Oxford OX3 7LE, ORCID ID 0000-0002-2026-6397; *Ian C K Wong*, Professor in Pharmacy Practice, Medicines Optimisation Research and Education (CMORE), Research Department of Practice and Policy, UCL School of Pharmacy and University College London Hospitals NHS Foundation Trust

Key words:

Word count (excluding title page, abstract, references, statements, figures and tables): 1714

Competing interest statement: None declared.

Number of supplementary files for online only publication: 0

Number of references: 22

Number of figures: 0

Number of tables: 30

Contributorship statement:

AS drafted the manuscript, undertaking the literature search and constructing the tables for each drug listed.

AS, MP, EH, MC, MM and IW jointly agree the drugs to include in the manuscript. MP, EH, MC, MM and IW had supervising input throughout the drafting the final manuscript.

Sources of Funding: None declared.

Ethical approval: None required.

Abstract

Background

Paediatric palliative care makes frequent use of orodispersible and transmucosal drug delivery routes. The limited published experience of this practice suggests that it enables the delivery of needle-free symptom relief, with the potential to train family carers in the community to administer anticipatory medications without reliance on trained health professionals.

Aims

To identify orodispersible and potential transmucosal alternatives that may be used in adults in the event of a patient having no oral or intravenous route and no access to subcutaneous injections.

Methods

The author panel identified medications through review of multiple drug formularies, review of the published evidence and their experience. Where possible, licensed alternatives were identified and any “off label” or unlicensed medications clearly highlighted.

Results

A practical list of 29 medications is provided which could be used either via the orodispersible or transmucosal alternative route for health care professionals delivering end of life care to consider in their practice when the licensed alternative routes are unavailable. All users of this guide are encouraged to use their professional judgement whenever selecting a medication for a patient, recognising that this review is neither a guideline nor a systematic review, and taking account of licensing considerations, adverse effects, potential unpredictability of time to effect, and contraindications.

Conclusion

Orodispersible and transmucosal medications offer the possibility of enabling rapidly delivered needle-free symptom relief. Should it be necessary to utilise these transmucosal alternatives then any experience gained should be reported either on www.palliativedrugs.com or in the format of published articles. Combined with further research, this experience offers the possibility of reducing injection frequency and inherent delays in medication administration, particularly in the community setting during the Covid-19 pandemic.

Aim

Our aim in writing this guide is to provide a resource from which healthcare professionals can select medications to control symptoms when in patients do not have an oral route and when injectable medications are not available. This will enable high quality needle-free palliative care, particularly in the community. We aim to summarise the evidence available regarding the transmucousal route, how transmucosal medications are administered, why they're effective and how transmucousal medications might be integrated into clinical practice.

Background

Transmucousal drug administration utilises the mucous membranes to deliver medication and is particularly beneficial when a patient cannot swallow tablets or liquids but does not have access to injectable medications or where the patient prefers to avoid injections. The mucosal membranes absorb lipophilic drugs rapidly, minimising first pass metabolism and therefore frequently leading to a rapid onset of effect. For these reasons transmucousal drug administration lends itself to use for rapid management of breakthrough symptoms. [1] The utilisation of transmucousal routes of administration is widely established in paediatrics.[2]

Prior to consideration of the transmucousal route it is important that every effort is made to utilise other available routes. In particular it is important to consider alternative formulations, such as, liquids in order to optimise the oral route before switching to a transmucosal alternative.

Examples of medications licenced and commonly used in the adult palliative population which utilise the transmucousal route include: nasal administration of fentanyl for pain; buccal administration of prochlorperazine for nausea and vomiting; orodispersible lansprazole for acid reflux; and rectal paracetamol for fever.

We defined methods of transmucosal drug administration as including buccal, sublingual, orodispersible, nasal and rectal routes. A pre-requisite to the use of transmucousal medications is that the mucosal membrane must be moist. There are several important general principles for transmucosal drug administration, which include:

1) Only soluble drug molecules can be readily absorbed via mucosal membrane. Therefore liquid preparations are preferable such as injection, concentrated solution or spray.

2) If chewable or oro-dispersible tablets are used it is critical to ensure sufficient saliva is available to dissolve the tablets or alternatively tablets may be dissolved prior to administration. Buccal hydration may be improved by 2 hourly ice chips, biotene oral gel or AS Orthna (contains porcine mucin).

3) To promote buccal or sublingual absorption keep the liquid in the mouth as long as possible without swallowing. Where the patient is not able to hold liquid in the mouth the prescriber may choose to use a buccal tablet and gently massage the outside of the cheek following administration.

4) The bioavailability of drugs is likely to be higher via transmucosal route compared to oral route but lower than via parenteral routes. The effect of the drug will depend on how long it can be retained next to the mucosa and any gastrointestinal absorption if the drug is swallowed.

5) To supply the patient or care giver with clear instructions on what each drug is being used for, how frequently it may be administered and how to administer each drug to avoid any administration errors, as well as any adverse effects to be aware of.

6) Patients need to be monitored and assessed when switched to a transmucosal route and adjust the dose as necessary.

7) It is best practice that injections prepared for sublingual or buccal administration are drawn up through a filter needle to reduce the risk of any glass injury to oral mucosa.

Furthermore, care needs to be taken to identify whether patients are swallowing or spitting out a large proportion of orally administered medications as this may further affect its efficacy. Taste is a particularly important factor as an unpleasant taste may make patients less likely to retain the medication on the buccal mucosa long enough for it to be effective. Anderson observed that:

“Buccal and sublingual administration, where there is considerable drug swallowed, results in lower plasma concentrations if that drug has a high first-pass effect because bioavailability is reduced.” [3]

In general, however, there is very limited pharmacokinetic and pharmacodynamic data available such as time to maximum concentration, time to maximum effect, and half-life when using the mucosal route for off licensed drug administration. The lack of data regarding “concentration–response relationship for either the beneficial or adverse effects”[3] of drugs means that adjustment of dose and frequency of administration to maximise efficacy and yet minimise adverse effects is very challenging.

Despite these caveats and considerations, transmucousal medications present the possibility of delivering needle free symptom control, something which is routinely employed in paediatric palliative care because “by and large, children hate needles.” [3]

Spathis and colleagues identified that this was an area of paediatric palliative care that had the potential to augment and enhance practice in adult palliative care:

“Family members can respond immediately to symptoms, without having to wait for the arrival of nursing staff. This approach could be of considerable value in adult community palliative care practice.” [4]

The Covid-19 pandemic raised concerns that availability of district nurses in the community to administer medications via the traditional subcutaneous route for adults approaching the end of their lives may be outstripped by the steep increase in demand for their services. Additionally, there is a need to ensure alternative medications are identified early so that this information is available to inform practice in the event of drug shortages.

Caution

All users of this guide are encouraged to use their professional judgement whenever selecting a transmucousal medication for a patient. The reader should note that this is neither a guideline nor a systematic review. Users must therefore consider their local and national guidelines, as well as considering the evidence base for the drug they elect to use, its licencing, contraindications to its use and adverse events. Any statements regarding a drug's licencing relate to its use in the United Kingdom only and users are advised to check the relevant licencing requirements if they are practicing in other countries around the world.

Methods

During the initial phase of the Covid-19 pandemic local, regional and national symptom management guidelines were created. [5,6,7,8,9,10,11,12,13,14,15] These were hand searched to identify potential transmucosal alternatives that might be of use in the event of a patient having no oral or intravenous route and no access to subcutaneous injections.

Transmucosal alternatives used in paediatric palliative care practice, both in the UK and internationally were explored. The experiences of expert colleagues working in a range of countries, was sought, both through personal communication and published work.

Having identified potential therapeutic options a list of alternative transmucoscal medications was compiled and cross referenced with the British National Formulary (BNF), the Palliative Care Formulary (PCF) and the Association of Paediatric Palliative Care (APPM) Formulary and the Enteral Drug Handbook as appropriate.[16,17,18,19]

The potential list of transmucosal medications were discussed and reviewed by the author panel until consensus was achieved.

Results

We identified 29 potential transmucosal alternative medications, listed below, and present the potential risks and benefits of each, their licensing status and costings, as listed in the BNF. We present an example table. See Tables 1-30.

Alfentanil Buccal, Sublingual or Nasal	
What is it?	Strong opioid analgesic – CD schedule 2 drug
Mechanism of action	Opioid having central agonist effect
Dose	10-16% of the total CSCI dose hourly prn
Time to onset of effect	5 minutes [17]
Formulation	Nasal spray with attachment for buccal/SL use (5mg/5mL) bottle available as special order from Torbay Hospital Manufacturing Unit Tel: 01803 664707. Each 'spray' delivers 0.14 ml = 140 microgram alfentanil OR Injection preparation given via buccal, sublingual or nasal route. Two strengths available, 500microgram/mL and 5mg/mL
Indication	Moderate to severe pain for the management of breakthrough, incident or procedural pain when eGFR <20
Common Adverse Effects	Apnoea; chills; fatigue; hypertension; movement disorders; muscle rigidity; procedural complications [16]
Contraindications	Avoid or use a reduced dose in hepatic failure[17]
Licencing	Nasal spray is an unlicensed product Injection is licensed but a transmucosal route is "off label"
Benefits	Rapidity of onset of action Ease of nasal administration
Risks	Prescribing/administration error Lack of familiarity with drug Lay carer administration Lack of availability Cost Unrecognised hepatic failure
Cost	Special – Price on Application (POA)

Table 1. Alfentanil Buccal, Sublingual or Nasal

Aripiprazole Orodispersible	
What is it?	Atypical antipsychotic
Mechanism of action	Aripiprazole is a dopamine D_2 partial agonist with weak 5-HT_{1a} partial agonism and 5-HT_{2A} receptor antagonism.
Starting dose	10mg
Time to onset of effect	3 – 5 hours [17]
Formulation	Orodispersible tablet
Indication	Agitated delirium
Common Adverse Effects	Anxiety; abnormal appetite; diabetes mellitus; fatigue; gastrointestinal discomfort; headache; hypersalivation; nausea; visual disorders [16]
Contraindications	CNS depression; cerebrovascular disease; comatose state; phaeochromocytoma [16]
Caution	Long half-life (75 – 145 hours) Elderly Hepatic failure
Licence	Licensed product
Benefits	Licensed product
Risks	Long half life
Cost	£25 - £96 for 28x 10mg tablets

Table 2. Aripiprazole Orodispersible

Atropine Sublingual	
What is it?	Antichloinergic
Mechanism of action	Non selective Antimuscarinic
Starting dose	4 drops (800 microgram – 1mg as size of drop varies)of 1% eye drops 4 hourly prn sublingually
Time to onset of effect	Uncertain (Half-life 2 – 2.5 hours) [17]
Formulation	1% eye drops
Indication	Sialorrhoea Noisy rattling breathing
Common Adverse Effects	Constipation; dizziness; drowsiness; dry mouth; dyspepsia; flushing; headache; nausea; palpitations; skin reactions; tachycardia; urinary disorders; vision disorders; vomiting [16]
Contraindications	Acute myocardial infarction; arrhythmias; autonomic neuropathy; cardiac insufficiency; cardiac surgery; diarrhoea; elderly; gastro-oesophageal reflux disease; hypertension; hyperthyroidism; narrow angle-closure glaucoma; ileus; prostatic hyperplasia; pyrexia; ulcerative colitis; myasthenia gravis [16]
Caution	Elderly
Licence	Unlicensed use and route for a licensed product
Benefits	Small volume Established body of use in palliative care practice
Risks	Varying dose with different droppers Systemic absorption
Cost	£131.89 for 10ml 1% eye drops

Table 3. Atropine Sublingual

Buprenorphine Sublingual	
What is it?	Strong opioid analgesic
Mechanism of action	Opioid having agonist and antagonist properties
Starting dose	200 micrograms every 6–8 hours prn (Equivalent to 15mg Morphine 6 – 8 hourly)
Time to onset of effect	10 – 20 minutes [17]
Formulation	Sublingual tablet – CD schedule 3 drug
Indication	Moderate to severe pain
Common Adverse Effects	Vomiting; Opioid adverse effects; constipation; dizziness; drowsiness; dry mouth [16]
Contraindications	Acute respiratory depression, comatose, head injury, raised intracranial pressure [16]
Caution	Those at risk of aspiration Severe hepatic impairment
Licence	Temgesic and Tephine are licensed products for pain
Benefits	May cause less constipation May cause less hyperalgesia
Risks	Systemic absorption Use complicated: Advise patients that tablets should be dissolved under the tongue, not to swallow for 2 minutes and not to consume food or drink for at least 5 minutes after administration Non registered carers will not be able to administer
Cost	£8.50 for 28x 200 microgram tablets

Table 4. Buprenorphine Sublingual

Carbamazepine Rectal	
What is it?	Analgesic – acting on neuropathic pain
Mechanism of action	Anti-epileptic sodium channel blocker
Starting dose	125mg bd
Time to onset of effect	4 to 8 hours [17]
Formulation	Suppository (125mg rectally is approximately equivalent to 100mg PO)
Indication	Neuropathic pain Seizures
Common Adverse Effects	Dizziness; drowsiness; dry mouth; eosinophilia; fatigue; fluid imbalance; gastrointestinal discomfort; headache; hyponatraemia; leucopenia; movement disorders; nausea; oedema; skin reactions; thrombocytopenia; vision disorders; vomiting; weight increased [16]
Contraindications	Acute porphyrias ; AV conduction abnormalities (unless paced); history of bone-marrow depression; Cardiac disease; history of haematological reactions to other drugs; may exacerbate absence and myoclonic seizures; skin reactions; susceptibility to angle-closure glaucoma [16]
Caution	Hepatic impairment Bone marrow suppression
Licence	Licensed product for seizure control; “off label” for neuropathic pain
Benefits	Licensed product
Risks	Expensive Lack of familiarity with this use in palliative care
Cost	£120 for 5 x 125mg suppositories

Table 5. Carbamazepine Rectal

Cyclizine Sublingual or Rectal	
What is it?	Antiemetic
Mechanism of action	Antihistaminic antimuscarinic antiemetic
Starting dose	50 mg bd - tds
Time to onset of effect	30 – 60 minutes [17]
Formulation	Injection given as a sublingual solution Rectal suppository (Must be kept in fridge)
Indication	Nausea related to raised intracranial pressure Nausea related gastrointestinal obstruction Nausea related to vestibular disorders
Common Adverse Effects	Anticholinergic adverse effects; Movement disorders, potential for misuse / abuse of injections
Contraindications	Epilepsy; prostatic hypertrophy (in adults); pyloroduodenal obstruction; severe heart failure—may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure; susceptibility to angle-closure glaucoma [16]
Caution	Renal and hepatic impairment
Licence	Use of injection orally: “off label” Use of suppositories: unlicensed product
Benefits	Alternative routes of administration
Risks	Delay to manufacture of suppositories
Cost	Oral solution: 50mg/ml ampoules for injection – £18.58 for 5 Suppository – a special order. Price of application (POA)

Table 6. Cyclizine Sublingual or Rectal

Diazepam Rectal	
What is it?	Benzodiazepine
Mechanism of action	$GABA_A$ modulator
Starting dose	2.5mg (approximately equivalent to 1.25mg Midazolam) 10mg for seizure
Time to onset of effect	30 minutes [17]
Formulation	Rectal tube
Indication	Agitated delirium Anxiety Seizures
Common Adverse Effects	drowsiness; fatigue; muscle weakness; nausea; respiratory depression (particularly with high dose and intravenous use—facilities for its treatment are essential); sleep disorders; vertigo; vision disorders; withdrawal syndrome [16]
Contraindications	Coma; current alcohol abuse; current drug abuse; respiratory depression [16]
Caution	Hepatic impairment Renal failure
Licence	Licensed for anxiety and seizures; “off label” for delirium
Benefits	Alternative route of administration
Risks	Greater evidence base with buccal midazolam than rectal diazepam
Cost	2.5mg - £5.65 for 5 5mg - £6.49 for 5 10mg - £6.49 for 5

Table 7. Diazepam Rectal

Diamorphine Intranasal or Sublingual	
What is it?	Strong opioid (CD Schedule 2)
Mechanism of action	Mu agonist
Starting dose	1.25 – 2.5mg 4 hourly prn (Equivalent to 3.75 – 7.5mg Morphine PO)
Time to onset of effect	<5 minutes [17]
Formulation	Nasal spray (Ayendi(R)) OR Injection (powder for reconstitution) intranasal or sublingual routes
Indication	Moderate to severe pain
Common Adverse Effects	Vomiting; Opioid adverse effects; constipation; dizziness; drowsiness; dry mouth [16]
Contraindications	Acute respiratory depression, comatose, head injury, raised intracranial pressure [16]
Caution	Those at risk of aspiration Severe hepatic and renal impairment
Licencing	Off license route of licensed injections Nasal spray (Ayendi(R)) licensed but not available in the UK at time of writing
Benefits	Rapidity of onset of action Ease of nasal administration
Risks	Prescribing/administration error Lack of familiarity with drug Lay carer administration and difficulty making up the drug
Cost	£12.81 for 5 x 5mg ampoules for injection; Ayendi (R) POA

Table 8. Diamorphine Intranasal or Sublingual

Diclofenac Rectal	
What is it?	Non opioid analgesic
Mechanism of action	Non-steroidal anti-inflammatory selective Cox-2 inhibitor
Starting dose	50mg 8 - 12 hourly prn
Time to onset of effect	30 minutes [17]
Formulation	Rectal suppository
Indication	Mild to moderate pain
Common Adverse Effects	Oedema; skin reactions; appetite decreased; diarrhoea; dizziness; gastrointestinal discomfort; gastrointestinal disorders; headache; nausea; rash (discontinue); vertigo; vomiting [16]
Contraindications	Allergy to aspirin, cardiovascular disease, gastrointestinal bleeding or history of perforation [16]
Caution	Hepatic impairment Renal failure [16]
Licence	Licensed
Benefits	Alternative route of administration
Risks	Difficult to administer
Cost	£1.24 for 10x 25mg or £2.04 for 10x 50mg suppositories

Table 9. Diclofenac Rectal

Docusate Rectal	
What is it?	Laxative
Mechanism of action	Faecal softener with some stimulant effect
Starting dose	120mg
Time to onset of effect	30 minutes [17]
Formulation	Rectal enema
Indication	Constipation
Common Adverse Effects	Abdominal discomfort, anorectal irritation, incontinence [16]
Contraindications	Bowel perforation [16]
Caution	Proctitis Intestinal obstruction
Licence	Licensed
Benefits	Alternative route of administration
Risks	Difficult to administer
Cost	£28.00 for 6x 120mg enemas

Table 10. Docusate Rectal

Domperidone Orodispersible	
What is it?	Antiemetic
Mechanism of action	Prokinetic D_2 antagonist
Starting dose	10mg prn tds
Time to onset of effect	30 minutes [17]
Formulation	10 mg orodispersible tab
Indication	Nausea and vomiting
Common Adverse Effects	Dry mouth; anxiety; asthenia; breast abnormalities; diarrhoea; drowsiness; headache; lactation disorders [16]
Contraindications	QT abnormality Prolactinoma [16]
Caution	Patients > 60
Licence	Orodisperible tablet unlicensed product
Benefits	Alternative route of administration
Risks	Extrapyramidal adverse effects
Cost	Orodispersible tablet –special POA

Table 11. Domperidone Orodispersible

Fentanyl Nasal, Buccal or Sublingual	
What is it?	Strong opioid(CD Schedule 2)
Mechanism of action	Mu agonist
Starting Dose	50 (Instanyl) to 100 micrograms (Pecfent, Abstral and Efentora) A further 50 or 100 micrograms after 15–30 minutes if required Maximum 2 doses per pain episode Dose titration as per manufacturer's guidance
Time to onset of effect	15 - 20 minutes [17]
Formulation	Pecfent® nasal spray Instanyl® nasal spray Abstral® sublingual tablet Effentora® buccal tablet
Indication	Moderate to severe pain for the management of breakthrough, incident or procedural pain
Common Adverse Effects	Acute respiratory depression, comatose, head injury, raised intracranial pressure
Contraindications	Those at risk of aspiration
Licence	Licensed product
Benefits	Rapidity of onset of action Ease of nasal administration
Risks	Lack of familiarity with drug Lay carer administration Mucositis when using buccal or sublingual products
Cost	Abstral - £49.99 for 10x 100microgram sublingual tablets; Effentora - £139.72 for 28x100microgram buccal tablets; Instanyl - £35.70 for 6x doses nasal spray 100micrograms/dose; Pecfent - £36.48 for 8 x doses nasal spray 100micrograms/dose.

Table 12. Fentanyl Nasal, Buccal or Sublingual

Glycopyrronium Sublingual	
What is it?	Antichloinergic
Mechanism of action	Antimuscarinic
Starting dose	200mcg 8 hourly prn sublingual
Time to onset of effect	30 – 40 minutes [17]
Formulation	Oral solution OR Injection
Indication	Drooling Noisy rattling breathing Medical management of malignant bowel obstruction Paraneoplastic fevers and sweating
Common Adverse Effects	Constipation; dizziness; drowsiness; dry mouth; dyspepsia; flushing; headache; nausea; palpitations; skin reactions; tachycardia; urinary disorders; vision disorders; vomiting [16]
Contraindications	Tachycardia >100 Cardiac conduction disorders [16]
Caution	Elderly Renal impairment – may need to reduce dose
Licence	Oral solution “off label” use in adults and “off label” route(however licensed for oral administration in children >3 years to adolescents with neurological disorders) Injection is a licensed product but “off label” route
Benefits	Small volume
Risks	Risk of glass ampoule when administering
Cost	£91 for 150ml x 200microgram/ml oral solution £76.80 for 60mls x 400mcg/ml oral solution £9.95 for 10x 200microgram/ml ampoules for injection

Table 13. Glycopyrronium Sublingual

Haloperidol Buccal or Sublingual	
What is it?	Butyrophenone antipsychotic
Mechanism of action	D_2, alpha-adrenergic and sigma receptor antagonist
Starting dose	0.5mg – 1.5mg 6 – 8 hourly
Time to onset of effect	I hour if give PO (buccal / sublingual may be faster) [17]
Formulation	Oral solution
Indication	Delirium Nausea and vomiting Hiccups Psychosis
Common Adverse Effects	Extra pyramidal effects, altered liver function tests, dizziness, sedation, visual disturbance, depression, hypotension [16]
Contraindications	Parkinson's disease, Lewy body dementia, cardiac disorders, QTc prolongation, recent myocardial infarction, decompensated heart failure heart failure [16]
Caution	Dementia, stroke risk, epilepsy, renal and hepatic impairment, cardiac disease [16]
Licence	Off licence use of licensed product
Benefits	Alternative route of administration of an antipsychotic
Risks	Time to effect unknown when used sublingually
Cost	*Price varies widely by product:* *£4.45 for 100ml of Haldol* 2mg/mL oral solution

Table 14. Haloperidol Buccal or Sublingual

Hyoscine hydrobromide Chewable	
What is it?	Antimuscarinic
Mechanism of action	Antisecretory with smooth muscle relaxant properties
Starting dose	150 microgram 4 hourly prn
Time to onset of effect	10 – 15 minutes [17]
Formulation	Chewable tablets
Indication	Sialorrhoea Drooling Smooth muscle spasm Paraneoplastic fevers and sweating
Common Adverse Effects	Constipation; dizziness; drowsiness; dry mouth; dyspepsia; flushing; headache; nausea; palpitations; skin reactions; tachycardia; urinary disorders; vision disorders; vomiting [16]
Contraindications	Tachycardia >100 Cardiac conduction disorders [16]
Caution	Crosses blood brain barrier so may cause sedation Elderly Renal and hepatic impairment May prefer to use transdermal patch
Licence	"off label" use of a licensed product
Benefits	Chewable alternative
Risks	Aspiration
Cost	£1.67 for 12x 150mg Kwells £1.99 for 12x 150microgram Joy-rides tablet

Table 15. Hyoscine hydrobromide Chewable

Ibuprofen Orodispersible or Chewable Capsule	
What is it?	Non opioid analgesic
Mechanism of action	Non-steroidal anti-inflammatory non- selective Cox inhibitor
Starting dose	200mg
Time to onset of effect	20-30 minutes onset [17]
Formulation	Orodispersible tablets or chewable capsule
Indication	Mild to moderate pain
Common Adverse Effects	Oedema; skin reactions; appetite decreased; diarrhoea; dizziness; gastrointestinal discomfort; gastrointestinal disorders; headache; nausea; rash (discontinue); vertigo; vomiting [16]
Contraindications	Allergy to aspirin or other NSAIDs, cardiovascular disease, gastrointestinal bleeding or history of perforation [16]
Caution	Hepatic impairment Renal failure
Licence	Licensed
Benefits	Licensed alternative route of administration
Risks	Worsening COVID , GI bleeding
Cost	£2.58 for 12x 200mg orodispersible tablets £3.23 for 12 x 100mg chewable capsule

Table 16. Ibuprofen Orodispersible or Chewable Capsule

Ipratropium Nasal	
What is it?	Antimuscarinic
Mechanism of action	Antisecretory with bronchodilator properties
Starting dose	41 micrograms (2 sprays) 6 – 8 hourly prn
Time to onset of effect	15 - 30 minutes [17]
Formulation	Nasal spray
Indication	Rhinorrhoea Bronchial secretions Respiratory secretions
Common Adverse Effects	Dizziness; dry mouth; headache; urinary disorders; vision disorders; vomiting; tachycardia; GI dysmotility; oropharyngeal irritation; bronchoconstriction [16]
Contraindications	Tachycardia >100 Cardiac conduction disorders [16]
Caution	Narrow angle glaucoma Bladder outflow obstruction Cystic Fibrosis
Licence	"off label" use of licensed product
Benefits	Easy to use
Risks	It is unknown whether sufficient systemic absorption is achieved via the intranasal route to improve bronchial and respiratory secretions
Cost	£6.54 for 180 x 21microgram/dose nasal spray

Table 17. Ipratropium Nasal

Levomepromazine Buccal or Sublingual	
What is it?	Anti-psychotic
Mechanism of action	Central nervous system (CNS); receptors include adrenergic, dopamine, histamine, cholinergic and serotonin receptors
Starting dose	3mg-25mg once daily (or 6.25-12.5mg as required maximum three times in 24 hours)
Time to onset of effect	Not known (30 minutes via oral route) [17]
Formulation	oral tablet crushed, with water 6.25- 25mg; OR 6mg tablets (Levinan®) 3mg (1/2 tablet) 4-6 hourly PRN (can be crush); OR injection 0.25-1ml sublingual
Indication	second line for nausea and vomiting or delirium and agitation
Common Adverse Effects	postural hypotension; falls; "Asthenia; heat stroke" [16]
Contraindications	"CNS depression; comatose states; phaeochromocytoma"[16]
Caution	Dementia, cardiac, prolonged QT, Parkinsonism, hypothyroidism, seizure, postural hyotension, myasthenia, renal and liver impairment [16]
Licencing	oral tablet licensed; Levinan is an unlicensed preparation available on a named patient basis; off licence route for injectable levoempromazine
Benefits	buccal administration of broad spectrum, long acting anti-psychotic*
Risks	injection concentration is 25mg/ml so challenging to administer 0.25ml, risk of injury from glass ampoule to lay carer
Cost	£20.26 for 84 x 25mg tablets £20.13 for 10 x 25mg/ml ampoules for injection; 6mg tablets – special POA

Table 18. Levomepromazine Buccal or Sublingual

*** Level of Evidence supporting its use (CBEM):** Level 5; Authors EH and IW have clinical experience of its use.

Loperamide Orodispersible	
What is it?	Anti-diarrheal agent
Mechanism of action	Opioid agonist effect on the large intestine
Starting dose	2–4 mg as needed maximum 4 times a day
Time to onset of effect	1 hour [17]
Formulation	orodispersible tablets
Indication	diarrhoea; colic
Common Adverse Effects	"Gastrointestinal disorders; headache; nausea" [16]
Contraindications	"Active ulcerative colitis; antibiotic-associated colitis; bacterial enterocolitis; conditions where abdominal distension develops; conditions where inhibition of peristalsis should be avoided" [16]
Caution	"Serious cardiovascular events (such as QT prolongation, torsades de pointes, and cardiac arrest)"[16]
Licencing	Licenced formulation
Benefits	a licenced orodispersible alternative for with good bioavailability in contrast to other alternatives such as hyoscine hydrobromide or glycopyrronium which have very low bioavailability when given via oral or buccal route
Risks	QT prolongation risk not yet widely recognised in clinical practice
Cost	£5.85 for 18 x 2mg orodispersible tablets

Table 19. Loperamide Orodispersible

Lorazepam Sublingual	
What is it?	Anxiolytic
Mechanism of action	Benzodiazepine
Starting dose	0.5-1mg
Time to maximal effect	2.5 hours [17]
Formulation	Tablet - can be halved
Indication	anxiety, panic, agitation
Common Adverse Effects	"Apnoea; asthenia; coma; disinhibition; extrapyramidal symptoms; hypothermia; memory loss; speech slurred; suicide attempt" [16]
Contraindications	Severe hepatic failure, untreated sleep apnoea, myasthenia gravis, severe respiratory failure [16]
Caution	"Avoid prolonged use (and abrupt withdrawal thereafter); debilitated patients (reduce dose) (in adults); elderly (reduce dose) (in adults); history of alcohol dependence or abuse; history of drug dependence or abuse; myasthenia gravis; personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence; respiratory disease" [16]
Licencing	Off license route of a licensed formulation
Benefits	sublingual benzodiazepine, widely used in usual practice
Risks	Common misconception that the sublingual route is licensed due to widespread use
Cost	£3.29 for 28 x 1mg tablets

Table 20. Lorazepam Sublingual

Miconazole Buccal	
What is it?	Azole anti-fungal
Mechanism of action	Disrupts the fungal cell member by inhibiting ergosterol synthesis
Starting dose	2.5ml four times a day oral gel; 50mg buccal tablet daily
Time to effect	Uncertain [17]
Formulation	oral gel or buccal tablet " Oral gel should be held in mouth, after food"[BNF] Buccal tablet is indicated for the treatment of oropharyngeal candidiasis in immunocompromised adults, Loramyc(R) 50 mg muco-adhesive buccal tablets should be applied to the upper gum just above the incisor tooth once daily for 7-14 days
Indication	oropharyngeal candidiasis
Common Adverse Effects	"skin reactions…dry mouth; nausea; oral disorders; vomiting" [16]
Contraindications	Pregnancy due to teratogenicity
Caution	CYP3A4 inhibitor; "Avoid in acute porphyrias" [16]
Licencing	oral gel licenced and available to buy over the counter; muco-adhesive buccal tablet not yet listed in the BNF, not recommended by Scottish Medicines Consortium
Benefits	over the counter, simple administration, licensed product
Risks	choking is listed as a side effect in children, adults with compromised swallow may therefore also be at risk of chocking, may not fully clear thrush if oesophageal involvement**
Cost	£4.38 for 80g x 20mg/g oromucosal gel; Loramyc(R) – special POA

Table 21. Miconazole Buccal

**** Level of Evidence supporting its use:** " Miconazole muco-adhesive buccal tablets were shown to be non-inferior to another locally-acting miconazole preparation in the treatment of oropharyngeal candidiasis in patients with cancer of the head and neck who had received radiotherapy. There are no data comparing miconazole buccal tablets to treatments currently used in practice in NHS Scotland. The manufacturer did not present a sufficiently robust analysis to gain acceptance by SMC. The licence holder has indicated their intention to resubmit." [21]

Morphine Rectal	
What is it?	Opioid analgesic
Mechanism of action	Mu opioid receptor antagonist
Starting dose	IR suppository 10mg PR As Required, maximum 2 hourly; conversion oral 1:rectal 1
Time to effect	45-60 minutes [17]
Formulation	Immediate release - suppositories are available as a specials order; when prescribing "Both the strength of the suppositories and the morphine salt contained in them must be specified by the prescriber."[16] Modified release - Morphine MST Continus® tablets given rectally
Indication	moderate to severe pain, breathlessness
Common Adverse Effects	"appetite decreased; asthenic conditions; gastrointestinal discomfort; insomnia; neuromuscular dysfunction" [16]
Contraindications	"Acute abdomen; delayed gastric emptying; heart failure secondary to chronic lung disease; phaeochromocytoma" [16]
Caution	See Direct.gov.uk for Drug Driving advice
Licencing	suppository licensed; rectal use of modified release tablets is an off licence use
Benefits	a transmucosal alternative to oral or subcutaneous morphine
Risks	unpredictability of bioavailability when rectal route used, "Delayed absorption of rectal morphine has contributed to respiratory arrest in infants." [3]
Cost	£19.45 for 12 x 10mg suppositories; £5.20 for 60 x 10mg modified release tablets

Table 22. Morphine Rectal

Morphine Sublingual	
What is it?	Opioid analgesic
Mechanism of action	Mu opioid receptor antagonist
Starting dose	2.5mg given as drops, up to hourly
Time to effect	Uncertain (16-60 minutes oral, but drug not lipophyllic therefore likely to be significantly longer) [17]
Formulation	20mg/1ml oral solution, designed for oral administration, risk of unpredictable absorption OR injection
Indication	pain, breathlessness
Common Adverse Effects	"appetite decreased; asthenic conditions; gastrointestinal discomfort; insomnia; neuromuscular dysfunction" [16]
Contraindications	"Acute abdomen; delayed gastric emptying; heart failure secondary to chronic lung disease; phaeochromocytoma" [16]
Caution	See Direct.gov.uk for Drug Driving advice
Licencing	"off label" route of licensed oral solution; "off label" route of licensed injection
Benefits	a transmucosal alternative to oral or subcutaneous morphine
Risks	best avoided due to unpredictability of bioavailability when buccal route used, likely lower than oral due to solution not being lipophilic, likely no advantage over oral administration
Cost	£19.50 for 120ml x 20 mg/ml oral solution; £11.47 for 10 x 10mg/ml ampoules for injection

Table 23. Morphine Sublingual

Olanzapine Orodispersible	
What is it?	Anti-psychotic
Mechanism of action	Antagonist to : D1, D2, D3, D4, 5HT(2A, 2C, 3, 6, 7), α1 and α2; anti-cholinergic
Starting dose	2.5mg -10mg prn ON initially, can be increased to BD
Time to onset of effect	Hours to days [17]
Formulation	orodispersible tabs (placed on the tongue & allowed to dissolve, or can be dissolved in small volume water/juice)
Indication	nausea and vomiting (low dose) or delirium and terminal agitation (higher dose)
Common Adverse Effects	"Anticholinergic syndrome; appetite increased; arthralgia; asthenia; eosinophilia; fever; glycosuria; oedema; sexual dysfunction" [16]
Contraindications	"Bone-marrow depression; hypereosinophilic disorders; low leucocyte count; low neutrophil count; myeloproliferative disease; paralytic ileus" [16] Narrow angle glaucoma [17]
Caution	Fatalities when injected due to over sedation or cardiorespiratory depression. Increased risk of this is co-administered with midazolam.
Licencing	"off label" use of licensed drug if used for nausea and vomiting
Benefits	improves mood, appetite, sleep as well as nausea and vomiting, and delirium ***
Risks	hyper somnolence, if used long term patients will require blood monitoring – lipids, FBC, BM
Cost	£6.86 for 28 x 5mg orodispersible tablets sugar free – those containing sugar are much more expensive

Table 24. Olanzapine Orodispersible

***Level of Evidence supporting its use as an anti-emetic (CBEM):** 1a (multiple meta-analyses) Number Needed to Treat to Benefit: 5; Number Needed to Treat to Harm: 19 [22]

Ondansetron Orodispersible or Rectal	
What is it?	Anti-emetic
Mechanism of action	Anti-serotonin 5HT3
Starting dose	buccal 4mg prn, max 16mg in 24 hours; rectal 16mg suppositories
Time to onset of effect	Uncertain (<30 minutes with oral route) [17]
Formulation	orodispersible film 4mg OR orodispersible tablets 4mg 6-8 hourly PRN max 16mg/24hr OR 16mg suppositories only dose available
Indication	nausea and vomiting
Common Adverse Effects	"Constipation; feeling hot; headache; sensation abnormal" [16]
Contraindications	"Congenital long QT syndrome" [16] Serious drug interaction with metoclopramide due to combined QT prolongation effect [17]
Caution	May reduce efficacy of tramadol and paracetamol [17]
Licencing	Licensed formulation for an "off label" indication in palliative care
Benefits	licenced orodispersible and rectal alternative anti-emetic
Risks	constipation, more costly than other alternatives such as olanzapine
Cost	£28.50 for 10 x 4mg or £57 for 10 x 8mg orodispersible films; £43.38 for 10 x 4mg or £85.43 for 10 x 8mg orodispersible tablets; £14.39 for 1 x 16mg suppository

Table 25. Ondansetron Orodispersible or Rectal

Oxycodone Sublingual	
What is it?	Opioid analgesic
Mechanism of action	Mu opioid agonist
Starting dose	1.25-2.5mg given as drops, maximum 1 hourly
Time to effect	Uncertain (20-30 minutes with oral route) [17]
Formulation	OxyNorm® Concentrate 10mg/ml oral solution
Indication	pain, breathlessness
Common Adverse Effects	" Anxiety; bronchospasm; depression; diarrhoea; dyspnoea; gastrointestinal discomfort; hiccups; mood altered; tremor"[16]
Contraindications	"Acute abdomen; chronic constipation; cor pulmonale; delayed gastric emptying" [16]
Caution	See Direct.gov.uk for Drug Driving advice
Licencing	"off label" route of licensed oral solution
Benefits	a transmucosal alternative to oral or subcutaneous morphine
Risks	unpredictability of bioavailability when sublingual or buccal route used, likely lower than oral due to solution not being lipophilic
Cost	£46.63 for 120ml x 10mg/ml oral solution

Table 26. Oxycodone Sublingual

Paracetamol Orodispersible or Rectal	
What is it?	Non-opioid analgesic
Mechanism of action	Weak COX2 and peroxidase inhhibitor
Starting dose	500mg -1000mg, maximum four times a day
Time to onset of effect	Uncertain (15-30 minutes with oral route) [17]
Formulation	Paracetamol FasTab 250mg oradispersible tablets (2-4 tablets per dose, dependent on weight and liver function) Paracetamol suppositories 1g; n.b. bioavailability is 60% compared with oral administration[3]
Indication	pain, fever
Common Adverse Effects	rectal “anorectal erythema” with rectal preparation [16]
Contraindications	severe liver dysfunction, 500mg QDS maximum if weight less than 50Kg
Caution	Olda age, poor nutritional state, fasting, anorexia, weight <50kg, chronic alcohol use [17]
Licencing	both are licensed formulation
Benefits	transmucosal alternatives for managing fever
Risks	ensuring correct number of orodispersible are used; ensuring that dose is reduced to 500mg QDS if weight less than 50kg or liver function tests severely deranged
Cost	£4.12 for 24 x 250mg orodispersible tablets (Fastmelts - would need 4 tablets per 1g dose); £59.50 for 10 x 1g suppositories

Table 27. Paracetamol Orodispersible or Rectal

Prochlorperazine Buccal	
What is it?	Anti-emetic
Mechanism of action	Antagonist to: D2, 5HT (2A and 2C), H1 and α1, and muscarinic receptors
Starting dose	3mg to 6mg every 12 hours [17]
Time to maximal effect	8 hours (4 hours with regular dosing)
Formulation	3mg orodispersible tablets (Buccastem)
Indication	dizziness, nausea
Common Adverse Effects	"Agitation; amenorrhoea; arrhythmias; constipation; dizziness; drowsiness; dry mouth; erectile dysfunction; galactorrhoea; gynaecomastia; hyperprolactinaemia; hypotension (dose-related); insomnia; leucopenia; movement disorders; neutropenia; parkinsonism; QT interval prolongation; rash; seizure; tremor; urinary retention; vomiting; weight increased" [16]
Contraindications	"CNS depression; comatose states; phaeochromocytoma" [16]
Caution	Photosensitivity
Licencing	Licensed formulation
Benefits	buccal alternative anti-emetic, widely used in clinical practice
Risks	oral and skin reactions possible, constipating
Cost	£27.61 for 50 x 3mg buccal tablets

Table 28. Prochlorperazine Buccal

Risperidone Orodispersible	
What is it?	Anti-psychotic
Mechanism of action	"Risperidone is a dopamine D2, 5-HT2A, alpha1-adrenoceptor, and histamine-1 receptor antagonist." [BNF]
Starting dose	0.5mg OD (can be increased to BD if needed)
Time to effect	Hours to days
Formulation	orodispersible tablet
Indication	delirium, terminal agitation
Common Adverse Effects	"Anaemia; anxiety; appetite abnormal; asthenia; chest discomfort; conjunctivitis; cough; depression; diarrhoea; dyspnoea; epistaxis; fall; fever; gastrointestinal discomfort; headache; hyperglycaemia; hypertension; increased risk of infection; joint disorders; laryngeal pain; muscle spasms; nasal congestion; nausea; oedema; oral disorders; pain; sexual dysfunction; skin reactions; sleep disorders; urinary disorders; vision disorders; weight decreased" [16]
Contraindications	Hypersensitivity to the active substance or to any of the excipients
Caution	"Avoid in Acute porphyrias; cataract surgery (risk of intra-operative floppy iris syndrome); dehydration; dementia with Lewy bodies; prolactin-dependent tumours" [16] Seizure, Parkinsonism, renal and liver failure, old age [16]
Licencing	"off label" use of a licensed formulation
Benefits	Orodispersible alternative anti-psychotic
Risks	narrower spectrum of action than olanzapine, currently not widely use outside of psychiatry
Cost	£18.28 for 28 x 500micrograms orodispersible tablets

Table 29. Risperidone Orodispersible

Tramadol Orodispersible	
What is it?	opioid (CD Schedule 3)
Mechanism of action	Mu opioid, SSRI, stimulate serotonin and noradrenaline
Starting dose	50mg maximum four times a day
Time to effect	Uncertain (30-60 minutes with oral) [17]
Formulation	orodispersible tablets
Indication	pain
Common Adverse Effects	"fatigue" [16]; hallucinations, delirium
Contraindications	"Acute intoxication with alcohol; acute intoxication with analgesics; acute intoxication with hypnotics; acute intoxication with opioids; compromised respiratory function (in children); not suitable for narcotic withdrawal treatment; uncontrolled epilepsy" [16]
Caution	Increased risk of seizure and serotonin syndrome
Licencing	Licensed formulation
Benefits	licensed orodispersible opioid
Risks	seizures, hallucinations
Cost	£7.12 for 60 x 50mg orodispersible tablets

Table 30. Tramadol Orodispersible

Discussion

Paediatric palliative has historically made greater use of oral transmucosal drug delivery for symptom relief in the community than adult palliative care. This practice offers an opportunity for rapid administration of needle-free symptom management in adults for whom transfer to hospital or hospice is not their preference or may be inappropriate, without delay inherent in subcutaneous medication administration by healthcare professionals in the community.

Use of licenced orodispersible medication in novel ways in adult palliative care has the potential to minimise the necessity for including “off license” or “unlicensed” products in the list above. Health care professionals should use licensed alternatives in preference to “off license” or “unlicensed” products. However, situations may arise where, due to the nature of a patients’ condition, symptom(s), or the complexity of the clinical situation (including drug and staff shortages), there are no licensed alternatives available. In these circumstances it is necessary to “give patients (or their carers) sufficient information about the medicines you propose to prescribe to allow them to make an informed decision”, answering any “questions from patients (or their carers) about medicines fully and honestly”. [20]

Therefore “off license” or “unlicensed” alternatives have been included above where the author panel agreed that there is sufficient evidence, clinical experience or expertise of their use.

Reporting of learning from the experience in using transmucosal drugs in adult palliative care in the literature is encouraged to inform future practice. If combined with further research this learning could lead to long-term changes in clinical practice, perhaps reducing the need for subcutaneous medication administration in the community in future.

Limitations

Due to the Covid-19 pandemic and the urgent need to generate a list of transmucosal medications there was insufficient time to undertake a rapid review of every medication listed above in order to establish an up to date evidence base for each.

It is outside the scope of this document to be able to offer guidance on the order of transmucosal drug selection to achieve symptom management, i.e. which drug would be first second or third line for any given symptom.

Unlicensed alternatives that have been reported in the literature but are not listed in the BNF, PCF or APPM are not included given that this list may be used by physicians who are not specialists in palliative medicine. Consequently, the list of transmucosal drugs in this article may not include all those which some specialist may elect to use.

Conclusion

Transmucosal medications offer the possibility of enabling rapidly delivered needle-free symptom relief in the community without the need to wait for a healthcare practitioner to visit.

A practical list of 29 medications have been identified and collated for health care professionals delivering care at the end of life to consider using in their practice. The list draws on existing knowledge of transmucosal delivery, in large part gained from clinical experience by colleagues in paediatric palliative care.

Should it be necessary to utilise this list of transmucosal drugs to deliver symptom management then any experience gained should be combined and reported either on www.palliativedrugs.com or in the format of published articles. Combined with further research, this experience offers the possibility of reducing injection frequency and inherent delays in medication administration, particularly in the community setting.

References

1. Kendall J, Maconochie I, Wong IC, Howard R, DIASAFE study; A novel multipatient intranasal diamorphine spray for use in acute pain in children: pharmacovigilance data from an observational study Emergency Medicine Journal, 2015 32(4):269-273
2. Lam JK, Xu Y, Worsley A, Wong IC, Oral transmucosal drug delivery for pediatric use, Advanced Drug Delivery Review. 2014 Jun 73:50-62
3. Anderson B, Goodbye to needles, Arch Dis Child 2013 98: 718-719
4. Spathis A, Harrop E, Robertshaw C, et al, Learning from paediatric palliative care: Lessons for adult practice, Palliative Medicine 2012 26: 777
5. COVID-19 management of End of Life symptoms – COMMUNITY SETTINGS, 24/3/2020 Version 1.3, Wessex Palliative Care Physicians 2020
6. Barnet Primary Care Guide During Covid-19 (Patient Age ≥ 12), Version 4.1: 25 March 2020
7. Community EOLC Alternative Meds Symptom Guidelines, March 2020, Oxfordshire, M Preslind
8. Clinical guide for symptom management using non-oral, non-parenteral routes of administration during the coronavirus pandemic, , March 2020, Oxfordshire, M Preslind
9. Symptom Control in the last days of life during COVID-19 pandemic, March 2020, Anonymous
10. Pre-emptive prescribing: COVID 19, Sheffield, March 2020, Anonymous
11. COVID-19 and Palliative, End of Life and Bereavement Care in Secondary Care Role of the specialty and guidance to aid care, 22 March 2020, Northern Care Alliance NHS Group and the Association for Palliative Medicine of Great Britain and Ireland by: Dr Iain Lawrie FRCP, MRCGP and Fiona Murphy MBE
12. Instruction sheet 3 for EMIS production, Anticipatory Meds Worksheet,V1.2, March 2020, SHFT/Solent NHS Trust
13. Non-injectable symptom control medication list, Palliative care team business continuity planning for Covid-19 March 2020, Anonymous
14. Supportive and Palliative Care Temporary Guideline, Additional Considerations During Pandemic Coronavirus Patients who are dying of causes other than Covid-19, March 2020 www.scottishpalliativecareguidelines.scot.nhs.uk, Accessed April 2020

15. EMERGENCY RESPONSE: Temporary End of LIFE CARE Symptom Control Guidance for Use in the COVID-19 crisis, Worcestershire and Herefordshire STP EOLC Emergency COVID 19 group 20 March 2020 Version 1, http://www.wmcares.org.uk/wmpcp/guide/, Accessed April 2020
16. British National Formulary (BNF) 79, BMJ Group and Pharmaceutical Press, March 2020
17. Palliative Care Formulary 6th Edition, Palliativedrugs.com Ltd, 2017
18. The Association of Paediatric Palliative Medicine Master Formulary (APPM) 5th edition, 2020www.appm.org.uk
19. Enteral Drug Handbook 3rd Edition, Pharmaceutical Press, 2015
20. Joint statement on community based prescribing for COVID-19 symptomshttps://content.govdelivery.com/accounts/UKCQC/bulletins/285a90b, Accessed 13.04.2020
21. Miconazole, https://www.scottishmedicines.org.uk/medicines-advice/miconazole-muco-adhesive-buccal-tablet-loramyc-fullsubmission-51708/, Accessed 03.04.2020
22. Sutherland A, Naessens K, Plugge E, et al, Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012555